Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, Ph.D., the Company’s newly appointed Chief Technical Officer, as a material inducement to her employment.